Redox-sensitive TRP channels: a promising pharmacological target in chemotherapy-induced peripheral neuropathy. (3rd July 2021)

• Record Type: Journal Article
• Authors: Singh, Ramandeep; Adhya, Pratik; Sharma, Shyam Sunder
• Is Part Of: Expert opinion on therapeutic targets. Volume 25:Number 7(2021)
• Page Start: 529
• Page End: 545
• Publication Date: 2021-07-03
• Subjects: Chemotherapy -- peripheral neuropathy -- neuropathic pain -- pathophysiological mechanisms -- oxidative stress -- redoxtrp -- pharmacotherapy -- chemotherapy-induced peripheral neuropathy -- cipn; Drugs -- Research -- Periodicals; 615.072
• DOI: 10.1080/14728222.2021.1956464
• Languages: English
• ISSNs: 1744-7631

Abstract

ABSTRACT: Introduction: Chemotherapy-induced peripheral neuropathy (CIPN) and its related pain is a major side effect of certain chemotherapeutic agents used in cancer treatment. Available analgesics are mostly symptomatic, and on prolonged treatment, patients become refractive to them. Hence, the development of improved therapeutics that act on novel therapeutic targets is necessary. Potential targets include the redox-sensitive TRP channels [e.g. TRPA1, TRPC5, TRPC6, TRPM2, TRPM8, TRPV1, TRPV2, and TRPV4] which are activated under oxidative stress associated with CIPN. Areas covered: We have examined numerous neuropathy-inducing cancer chemotherapeutics and their pathophysiological mechanisms. Oxidative stress and its downstream targets, the redox-sensitive TRP channels, together with their potential pharmacological modulators, are discussed. Finally, we reflect upon the barriers to getting new therapeutic approaches into the clinic. The literature search was conducted in PubMed upto and including April 2021. Expert opinion: Redox-sensitive TRP channels are a promising target in CIPN. Pharmacological modulators of these channels have reduced pain in preclinical models and in clinical studies. Clinical scrutiny suggests that TRPA1, TRPM8, and TRPV1 are the most promising targets because of their pain-relieving potential. In addition to the analgesic effect, TRPV1 agonist-Capsaicin possesses a disease-modifying effect in CIPN through its restorative property in damaged sensory nerves.